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Abstract: Chondroitin-sulfate proteoglycan 4 (CSPG4) is a transmembrane glycoprotein
overexpressed on malignant cells in several cancer types with only limited expression on normal
cells. CSPG4 is implicated in several signaling pathways believed to drive cancer progression,
particularly proliferation, motility and metastatic spread. Expression may serve as a prognostic
marker for survival and risk of relapse in treatment-resistant malignancies including melanoma, triple
negative breast cancer, rhabdomyosarcoma and acute lymphoblastic leukemia. This tumor-associated
overexpression of CSPG4 points towards a highly promising therapeutic target for antibody-guided
cancer therapy. Monoclonal αCSPG4 antibodies have been shown to inhibit cancer progression
by blocking ligand access to the CSPG4 extracellular binding sites. Moreover, CSPG4-directed
antibody conjugates have been shown to be selectively internalized by CSPG4-expressing cancer cells
via endocytosis. CSPG4-directed immunotherapy may be approached in several ways, including:
(1) antibody-based fusion proteins for the selective delivery of a pro-apoptotic factors such as tumor
necrosis factor-related apoptosis-inducing ligand to agonistic death receptors 4 and 5 on the cell
surface; and (2) CSPG4-specific immunotoxins which bind selectively to diseased cells expressing
CSPG4, are internalized by them and induce arrest of biosynthesis, closely followed by initiation
of apoptotic signaling. Here we review various methods of exploiting tumor-associated CSPG4
expression to improve targeted cancer therapy.
Keywords: cancer; immunotherapy; CSPG4; HMW MAA; MCSP; antibody drug conjugates;
immunotoxins; targeted human cytolytic fusion proteins (hCFP); ETA; MAP tau; angiogenin; TNF
ligands; TRAIL
1. Introduction
Chondroitin sulphate proteoglycan 4 (CSPG4), alternatively known as melanoma-associated
chondroitin-sulphate proteoglycan (MCSP) or high molecular weight melanoma-associated antigen
(HMW MAA), is a membrane-integral chondroitin sulphate (CS)-modified glycoprotein-proteoglycan
(Figure 1). The amino acid sequence of CSPG4 is highly species conserved, showing over 80% homology
with the rat neuroglial-2 proteoglycan (NG2) and the mouse AN2 antigen [1]. The 250 kD glycoprotein
Biomedicines 2017, 5, 37; doi:10.3390/biomedicines5030037 www.mdpi.com/journal/biomedicines
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core protein is composed of a large CS-modifiable extracellular region, a 45-amino acid hydrophobic
transmembrane region and a short 75-amino acid cytoplasmic region [2,3].
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Figure 1. Schematic representation of Chondroitin sulphate proteoglycan 4 (CSPG4) protein domain 
organization. The CSPG4 protein consists of three extracellular domains (D1 to 3), a transmembrane 
region (red) and a short cytoplasmic domain. Ligand binding sites for laminin G are indicated in D1 
(purple ovals). The extracellular domain is variably subject to glycosylation. 
The extracellular region of CSPG4 consists of three domains (D1–3), with D1 most distal from 
the membrane and D3 most proximal to the cell membrane. Each of these domains has distinct 
structural and functional properties, including binding domains for growth factors and other ligands 
that constitutively activate mitogenic pathways and transcription [3,4]. The N-terminal domain D1 is 
characterized by various signaling regions, including a laminin globular (G) domain. D2, the largest 
extracellular domain, is rich in serine and glycine and includes collagen V and VI binding sites. 
Characteristically, this domain also comprises several sites for N- and O-linked glycosylation and 
chondroitin sulfate glycosaminoglycan (CSGAG) modification. CS addition takes place in the Golgi 
apparatus and the degree of glycosylation can increase the size of the protein to over 500 kD [5]. This 
modification is seemingly not required for signal transduction functionalities of the CSPG4, although 
it does mediate differential ligand binding [6]. D3, a small globular region, is the most C-terminal of 
the extracellular part of CSPG4 and is exclusively subject to N-linked glycosylation. 
The cytoplasmic tail includes ERK and PKCα phosphorylation sites (in the form of a threonine 
cluster region) [7], as well as a PDZ-motif involved in anchoring the membrane-bound CSPG4 to the 
actin cytoskeleton. Downstream, threonine phosphorylation of this intracellular region of CSPG4 by 
ERK/PKCα activates cell proliferation and survival pathways (such as the PI-3K/AKT/mTOR 
pathway), increases cell motility and epithelial-mesenchymal transition (via FAK and Rho family 
proteins, Rac1 and cdc42), as well as promoting hormone/radiation therapy resistance (via activated 
cdc42, or ACK1) [5,8,9]. 
The presence of the above-mentioned extracellular ligand binding domains and intracellular 
signaling motifs implicates CSPG4 in the regulation (and deregulation) of cell cycle pathways, 
promoting oncogenic transformations such as epithelial-mesenchymal transition (EMT). Cells that 
should become terminally differentiated are thus driven by inappropriate expression of CSPG4 to 
develop characteristics similar to stem cells, such as self-renewal and motility. The relationship 
between normal CSPG4 expression and tumor-related overexpression will be discussed in the 
following section. Regulation of CSPG4 expression appears to depend on post-translational 
modification—DNA hypomethylation of CpG islands in the CSPG4 promoter has been proposed as 
potential cause for deregulation of CSPG4 expression, resulting in sustained overexpression in cells 
that normally would have downregulated CSPG4 levels [10]. 
Figure 1. Schematic representation of Chondroitin sulphate proteoglycan 4 (CSPG4) protein domain
organization. The CSPG4 protein consists of three extracellular domains (D1 to 3), a transmembrane
region (red) and a short cytoplasmic domain. Ligand binding sites for laminin G are indicated in
D1 (purple ovals). The extracellular domain is variably subject to glycosylation.
The extracellular region of CSPG4 consists of three domains (D1–3), with D1 most distal from
the membrane and D3 most proximal to the cell membrane. Each of these domains has distinct
structural and functional properties, including binding domains for growth factors and other ligands
that constitutively activate mitogenic pathways and transcription [3,4]. The N-terminal domain D1 is
characteriz d by variou sign ling regions, including a laminin globular (G) domain. D2, the largest
extracellular domain, is rich i serine and glycine and ncludes collagen V and VI binding sites.
Characteristic lly, this domain also comprises several sites for N- and O-linked glycosylation and
chondroitin sulfate glycosaminoglycan (CSGAG) modification. CS addition takes place in the Golgi
apparatus and the degree of glycosylation can increase the size of the protein to over 500 kD [5].
This modification is seemingly not required for signal transduction functionalities of the CSPG4,
although it does mediate differential ligand binding [6]. D3, a small globular region, is the most
C-terminal of the extracellular part of CSPG4 and is exclusively subject to N-linked glycosylation.
The cytoplasmic tail includes ERK and PKCα phosphorylation sites (in the form of a threonine
cluster region) [7], well as a PDZ-motif involved in anchoring the membrane-bound CSPG4 to the
actin cytoskeleton. Downstream, threonine phosph ryl tion f t is int acellular region of CSPG4
by ERK/PKCα activates cell proliferation and survival pathways (such as the PI-3K/AKT/mTOR
pathway), increases cell motility and epithelial-mesenchymal transition (via FAK and Rho family
proteins, Rac1 and cdc42), as well as promoting hormone/radiation therapy resistance (via activated
cdc42, or ACK1) [5,8,9].
The presence of the above-mentioned extracellular ligand binding domains and intracellular
signaling motifs implicates CSPG4 in the regulation (and deregulation) of cell cycle pathways,
promoting oncogenic transformations such as epithelial-mesenchymal transition (EMT). Cells that
should be ome terminally differen iated are thus riven by inap r priate expr ssion f CSPG4 to
devel p char cteristics similar to stem cells, such as e f-renewal a d motility. The relationship
between normal CSPG4 expressio and tumor-related overexpression will be discussed in the following
section. Regulation of CSPG4 expression appears to depend on post-translational modification—DNA
hypomethylation of CpG islands in the CSPG4 promoter has been proposed as potential cause for
deregulation of CSPG4 expression, resulting in sustained overexpression in cells that normally would
have downregulated CSPG4 levels [10].
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CSPG4 Expression in Health and Disease
CSPG4 is heterogeneously expressed in stem-cells and adult progenitor cells [11] such as
epidermal stem cells [12], naive and (to a greater degree) activated pericytes—the latter being associated
with wound healing and a range of fibrotic pathologies [13,14]. In normal adult tissues, expression
appears to be post-translationally downregulated at terminal differentiation [6,15], while elevated
expression in adult tissues is associated with poorly-differentiated and EMT-characterized cells with
tumor forming potential [5,9]. Upregulation of CSPG4 in malignant tumors is putatively linked to their
ability to bypass inherent regulatory mechanisms by suppressing apoptotic signaling, proliferating at
an elevated rate and acquiring anchorage independence. This is evident from the observation that
treatment with an anti-CSPG4 monoclonal antibody (mAb) results in reduced growth and motility of
melanoma cells [16].
CSPG4 is becoming increasingly implicated in several of the most aggressive and
treatment-resistant forms of cancer, including malignant melanoma [3,17], basal-like breast cancers,
leukemia, mesothelioma, glioblastoma multiforme, soft-tissue sarcomas, pancreatic carcinoma and
squamous cell carcinoma of the head and neck (HNSCC) [4,18–25]. CSPG4 overexpression is
particularly associated with mid-to-late transformation stages, from proliferative to early invasive
and migratory stages of tumor progression [3,9], such as in the progression of melanoma tumors from
radial growth phase (RGP) to vertical growth phase (VGP).
Of particular interest is the fact that CSPG4 is also putatively expressed by cancer stem cells
(CSCs) [4]. CSCs are poorly differentiated, self-renewing cancer cells with highly regenerative,
migratory and tumor forming ability [23–25]. CSCs represent a small but distinct subpopulation within
tumors that are particularly resistant to several modes of cytotoxic therapy. This resilient phenotype
allows CSCs to re-establish local and/or distal tumors even after seemingly complete eradication of
tumors by conventional therapy [4,26]. This feature furthers the value of CSPG4 expression in cancer
as a prognostic marker, particularly pertaining to metastasis, treatment resistance and probability
of relapse.
CSPG4 possesses no known catalytic function of its own, however it is able to facilitate constitutive
activation of signaling pathways which promote cell proliferation, migration and invasion [9].
Via various binding sites dispersed in its large extracellular domain, CSPG4 interacts with several
ligands, such as growth factors, in the extracellular space. For example, fibroblast growth factor
(FGF) and platelet-derived growth factor AA (PDGF-AA) associate with CSPG4, which in turn
mediates binding to their respective receptors and protects their protease-sensitive basic Lys and
Asp/Arg-rich adhesion sites from extracellular degradation [15]. Consequently, the association of
FGF and PDGF-AA with CSPG4 promotes their activation of the intracellular Ras-RAF-MEK-MAPK
and PI-3K/AKT/mTOR pathways, which enhance gene transcription, ultimately promoting cell
proliferation and cell migration [26]. Moreover, together with melanoma cell adhesion molecule
(MCAM), CSPG4 is also implicated as a mediator of PAX3 (of the paired box or PAX family) signaling.
PAX3 is a developmentally important transcription factor which, in adults, is highly implicated in
melanoma progression, promoting a poorly-differentiated and migratory phenotype [27].
Additionally, CSPG4 is known to cooperate with integrins, transmembrane proteins which interact
with extracellular matrix (ECM) components such as collagen, fibrinogen, galectin-3, fibronectin,
vascular cell adhesion molecule (VCAM1) and cell-surface syndecans [28]. CSPG4 acts as co-receptor
with α4β1 integrin in associating with both fibronectin and VCAM1, triggering integrin clustering and
fibronectin matrix assembly [8]. Galectin-3, a lectin family member strongly associated with tumor
metastasis, has been shown to form a complex with α4β1 integrin and CSPG4 [6]. Clustering of CSPG4
and integrins also induces activation of the Rho family of GTPases [29], which regulate the formation
of cytoskeletal extensions characteristic of migratory cells, such as filopodia, via phosphorylation
and recruitment of focal adhesion kinase (FAK) and, further downstream, phosphorylation of
p130cas, a docking protein credited for mediating anchorage independence [8,29,30]. Furthermore,
CSPG4 has also been shown to bind (in a CSGAG dependent manner) to membrane type-3 matrix
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metalloproteinase (MT3-MMP) and its substrate proMMP-2, presenting proMMP-2 to MT3-MMP for
activation resulting in downstream promotion of cell migration [31].
Taken together, CSPG4 is overexpressed in multiple difficult-to-treat cancers in which it is
a prominent player in promoting tumor progression and metastasis via various modes of action.
Practically, such a central oncogenic role may represent a druggable Achilles’ heel for rational-designed
CSPG4-targeted cancer therapy.
For the purposes of this review, we recognize CSPG4 as a marker for aggressive, therapy-resistant
cancers and are particularly interested in its potential as target for tumor-selective oncolytic agents
such as antibody-drug conjugates (ADCs), immunotoxins (ITs) and tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL) fusion proteins, described later in this review.
2. CSPG4 as Target for Cancer Therapy
Several mAb targeting CSPG4 have been described which inhibit growth and progression of
CSPG4-positive tumors, including mAb 9.2.27 (against melanoma [16]), mAb 225.28 (against breast
cancer [18]) and mAb TP41.2 (against mesothelioma [21]). The antitumor activity of anti-CSPG4
mAb 9.2.27 appeared to be largely attributable to its ability to block binding of the afore mentioned
ECM-associated ligands to the extracellular domain of CSPG4 [16]. Similarly, the anti-CSPG4 mAb
225.28 potently suppressed proliferation and metastasis in CSPG4+ breast cancer cells by inhibiting
CSPG4-mediated survival-promoting signaling pathways [18]. Moreover, Chang and co-workers
provided supporting evidence for non-immunological mechanisms by which anti-CSPG4 mAbs
affect the biology of melanoma cells [32]. Rivera and co-workers monitored the downstream
signaling components involved in CSPG4-mediated ECM interactions and found that TP41.2 inhibited
cell-adhesion dependent survival in malignant mesothelioma [21].
Therapy with conventional naked murine antibodies is known to have only limited anti-tumor
activity in vivo. This may be explained by various mutually reinforcing negative factors, including high
immunogenicity, reduced serum half-life and an inability to adequately recruit human cytotoxic effector
mechanisms such complement dependent cytotoxicity (CDC) and antibody dependent cell-meditated
cytotoxicity (ADCC). Furthermore, antibodies as such have relative high molecular weights and
bulkiness that limit their penetration of solid tumors.
Antibody engineering has been applied to address these and other issues. This has led
to the construction of novel CSPG4-targeted antibody-based agents with significantly enhanced
anticancer activity. ITs represent a broad range of ADCs that enable selective delivery and subsequent
internalization of cytotoxic drugs into tumor cells (Figure 2). ADCs can be generated by chemical
conjugation of a toxic agent to a conventional antibody via a conditionally stable linker [33]. Ideally,
this linker should remain fully intact until the ADC binds to the target cell, only releasing the toxic
drug moiety upon internalization [33]. Recently, a novel biocompatible CSPG4-targeted ADC format,
designated HFt-Pt-Ep1, was described in which up to three molecules of the anti-CSPG4 mAb Ep1
were conjugated to a single human ferritin (HFt) cage encapsulating up to 50 cisplatin molecules.
Treatment of CSPG4+ cancer cells selectively and effectively inhibit thymidine incorporation with
negligible effect on CSPG4-negative cell lines [34].
Antibody technology has been improved significantly by the advent of antibody-phage display
libraries, which permits panning out of unique disease-specific antibody fragments for use as building
blocks to construct fully functional antibodies and derivatives thereof [35]. This method has also
enabled the selection of fully human single chain variable antibody fragments (scFv’s), some of which
have been used to replace non-human antibody domains from conventional ADCs, thereby reducing
the risk of immunogenicity when applied in humans.
Moreover, presumably due to smaller size, scFv antibodies may show improved tumor penetration
compared to their mAb and Fab2 counterparts [36], while maintaining target tissue specificity. In the
context of this review is worth mentioning that a human anti-CSPG4 antibody derivative, scFv-Fc21,
has been shown to inhibit tumor growth and migration similarly to its full mAb counterpart [37].
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conjugated to a chemotherapeutic drug; Fusion protein: 3rd generation (bacterial/viral effector) and 
4th generation (human effector). Recombinant proteins enable the introduction of a variety of adaptor 
peptides to facilitate cytosolic delivery (blue rectangle). 
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Protein-based ITs consist of a disease-specific antibody fragment (targeting domain) 
recombinantly fused to a cytotoxic protein, such as Exotoxin A (effector domain) separated by 
intramolecular peptide linker [38]. In general, ITs exhibit acceptable tumor penetration and serum 
stability. Improved tumor penetration is achieved by using a tumor-targeting scFv (or nanobody) 
[36] and the smallest truncated form of a protein toxin that still retains its cytotoxicity. This approach 
yields a much smaller drug molecule than the first-generation full-length mAb and full-length toxin 
versions. Protein engineering technology has also been used to design ranges of peptide linker 
variants, including linkers with elements that facilitate production and purification, as well as those 
that improve serum stability and influence intracellular routing of the IT [39–41]. 
Exotoxin A (ETA) is a potent cytotoxic protein produced by Pseudomonas aeruginosa, ETA 
consists of three functional domains: a cell binding domain (I), an intracellular membrane 
translocation domain (II) and an adenosine diphosphate (ADP)-ribosylating domain (III) [42]. 
Domain III is responsible for the toxicity of ETA by inactivating elongation factor 2 (EF-2) via ADP-
ribosylation, interrupting protein production and inducing cell death with great potency 
(theoretically, a single molecule ETA can induce full arrest of cellular biosynthesis). Already in the 
early stages of IT development, ETA was recognized as a cytotoxic effector domain with promising 
anticancer activity [43]. The intrinsic cell binding and translocation capacity of full-length ETA 
ensures cytosolic delivery of the toxic domain III. However, these same characteristics of ETA are 
also the source of tumor specificity problems, as non-specific cell binding leads to off-target toxicity. 
This problem was largely overcome by employing a truncated form of ETA (ETA′) which lacks its 
cell binding Domain Ia [44], such as used in an ETA′-based IT targeting MSCP (CSPG4) recently 
generated by Brehm and co-workers [21] using a novel bacterial expression system [45]. 
In the following sections, we will provide a short overview of CSPG4-targeting scFv-fusion 
proteins which have been preclinically evaluated for efficacy towards various refractory cancer types, 
in particular in rhabdomyosarcoma (RMS), a soft-tissue sarcoma occurring in young children (in the 
form of embryonal RMS, eRMS) as well as older children and adults (typically alveolar or 
pleomorphic RMS, aRMS or pRMS) [46]. The different forms of RMS have distinct molecular origins 
and can occur in a wide range of tissues, hence a combination of conventional therapeutic modalities 
is recommended for the treatment of these resilient neoplasms. Unfortunately, those treatments are 
associated with adverse long-term effects and shortened life-expectancy [47]. 
Figure 2. Immunotoxins comprising antibodies linked to an anti-cancer agent. The scFv portion
(yellow frame) of the monoclonal antibody (green frame) retains antigen specificity and binding
capacity. Antibody drug conjugate: 1st generation (monoclonal antibody) and 2nd generation (scFv),
conjugated to a chemotherapeutic drug; Fusion protein: 3rd generation (bacterial/viral effector) and
4th generation (human effector). Recombinant proteins enable the introduction of a variety of adaptor
peptides to facilitate cytosolic delivery (blue rectangle).
3. Anti-CSPG4 Immunotoxins
Protein-based ITs consist of a disease-specific antibody fragment (targeting domain) recombinantly
fused to a cytotoxic protein, such as Exotoxin A (effector domain) separated by intramolecular peptide
linker [38]. In general, ITs exhibit acceptable tumor penetration and serum stability. Improved tumor
penetration is achieved by using a tumor-targeting scFv (or nanobody) [36] and the smallest truncated
form of a protein toxin that still retains its cytotoxicity. This approach yields a much smaller drug
molecule than the first-generation full-length mAb and full-length toxin versions. Protein engineering
technology has also been used to design ranges of peptide linker variants, including linkers with
elements that facilitate production and purification, as well as those that improve serum stability and
influence intracellular routing of the IT [39–41].
Exotoxin A (ETA) is a potent cytotoxic protein produced by Pseudomonas aeruginosa, ETA consists
of three functional domains: a cell binding domain (I), an intracellular membrane translocation domain
(II) and an adenosine diphosphate (ADP)-ribosylating domain (III) [42]. Domain III is responsible for
the toxicity of ETA by inactivating elongation factor 2 (EF-2) via ADP-ribosylation, interrupting protein
production and inducing cell death with great potency (theoretically, a single molecule ETA can induce
full arrest of cellular biosynthesis). Already in the early stages of IT development, ETA was recognized
as a cytotoxic effector domain with promising anticancer activity [43]. The intrinsic cell binding and
translocation capacity of full-length ETA ensures cytosolic delivery of the toxic domain III. However,
these same characteristics of ETA are also the source of tumor specificity problems, as non-specific cell
binding leads to off-target toxicity. This problem was largely overcome by employing a truncated form
of ETA (ETA′) which lacks its cell binding Domain Ia [44], such as used in an ETA′-based IT targeting
MSCP (CSPG4) recently generated by Brehm and co-workers [21] using a novel bacterial expression
system [45].
In the following sections, we will provide a short overview of CSPG4-targeting scFv-fusion
proteins which have been preclinically evaluated for efficacy towards various refractory cancer types,
in particular in rhabdomyosarcoma (RMS), a soft-tissue sarcoma occurring in young children (in the
form of embryonal RMS, eRMS) as well as older children and adults (typically alveolar or pleomorphic
RMS, aRMS or pRMS) [46]. The different forms of RMS have distinct molecular origins and can occur
in a wide range of tissues, hence a combination of conventional therapeutic modalities is recommended
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for the treatment of these resilient neoplasms. Unfortunately, those treatments are associated with
adverse long-term effects and shortened life-expectancy [47].
Brehm and co-workers screened their αMCSP-ETA′ compound for differential binding and
cytotoxic activity towards notoriously aggressive CSPG4+ eRMS and aRMS cell lines (RD, FL-OH1,
TE-671 and Rh30) versus a CSPG4-negative lymphoma line (Figure 3). Preferential binding of
αMCSP-ETA′ was detected in all RMS lines and in primary RMS patient-derived cancer cells. Moreover,
upon binding rapid internalization of αMCSP-ETA′ was observed in all RMS cell lines, while no
binding or internalization was observed for the CSPG4− U937 lymphoma cells. Importantly, in vitro
treatment with αMCSP-ETA′ inhibited cell proliferation and promoted apoptosis in all CSPG4+ lines
tested at low nanomolar range, while sparing CSPG4− cells. Additionally, a non-targeting mock IT
(Mock-ETA′) did not have any effect on the MCSP+ RMS cells.
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Figure 3. Binding analysis of αCSPG4-ETA′ (αMCSP-ETA′) immunotoxin to rhabdomyosarcoma 
(RMS) cell lines (RD, TE-671, Rh30 and FL-OH1) versus CSPG4− U937 lymphoma cells. All cells lines 
were incubated with αCSPG4 mAb or αMCSP-ETA′ and analyzed by flow cytometry. Reprinted from 
Brehm et al (2014) with permission from Elsevier [24]. 
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toxicities due to their inherent infectious nature. Truncated versions of ETA (ETA′) have been 
implemented, primarily retaining domains II (membrane translocation capacity) and domain III 
(ADP-ribosyltransferase activity) of the full virulence factor [48]. However, ETA′-based ITs still hold 
limited potential for clinical applications due to their immunogenicity in humans, an obstacle recently 
being addressed by the depletion of recognized B-cell epitopes on the IT [49]. In this respect, entirely-
human ITs, in which both the targeting moiety and effector protein are of human origin, are 
representing a very attractive solution: recombinant human cytolytic fusion proteins (hCFPs) present 
a viable alternative, allowing repeated administrations without requiring compensatory dose 
increases. 
Having established the specific anticancer activity of αMCSP-ETA′ in CSPG4+ RMS cell lines, 
Brehm and co-workers proceeded to develop and test pro-apoptotic human proteins as potential 
hCFP candidates [50] to replace ETA′, including the cytotoxic protein MAP tau. 
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Having established the specific anticancer activity of αMCSP-ETA′ in CSPG4+ RMS cell lines,
Brehm and co-workers proceeded to develop and test pro-apoptotic human proteins as potential hCFP
candidates [50] to replace ETA′, including the cytotoxic protein MAP tau.
Microtubule-associated protein tau (MAP tau) is most commonly associated with neurobiology
research due to its implication in Alzheimer’s disease [51]. The timely polymerization and
de-polymerization of microtubules is crucial for mitosis [52], a process which is highly upregulated in
cancer cells. The rationale behind exploiting MAP tau as a cytotoxic effector domain is based on its
ability to bind to and stabilize microtubule polymerization, disrupting mitosis and ultimately arresting
cell division [53]. Employing MAP tau as a cytolytic effector has two major benefits: (a) it is a fully
human apoptosis-inducing protein; and (b) it has no known endogenous inhibitors, which may reduce
its efficacy as a cytolytic agent.
Amoury and co-workers generated a CSPG4-targeting hCFP by replacing ETA′ with MAP
tau as cytolytic effector [54]. The resulting αCSPG4(scFv)-MAP tau was similarly evaluated for
binding and internalization in CSPG4+ human triple-negative breast cancer (TNBC) cell lines,
alongside CSPG4− mammary carcinoma lines. TNBC is a highly aggressive and treatment-resistant
breast cancer characterized by the absence/under-expression of three commonly targeted receptors:
estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor
II (HER2). This profile, also commonly seen in basal-like breast cancers, renders tumors resistant
to endocrine-receptor targeted therapy, making non-surgical treatment of such subsets of breast
cancer somewhat challenging. Furthermore, both basal and TNBC classifications are associated
with the presence of cancer stem cell (CSC) populations, which are implicated in the renewal and
therapy-resistance of several types of solid tumors [55]. As previously mentioned, CSPG4 has been
identified as a marker both for CSCs [4,26] and for TNBC [15], providing further support of its potential
as target antigen for hCFP therapy in TNBC.
Indeed, an αCSPG4(scFv)-MAP tau exhibited specific binding to CSPG4+ TNBC lines
MDA-MB-231 and Hs578T, with no binding to CSPG4− MDA-MB-468 cells. Importantly, internalization
of αCSPG4(scFv)-MAP tau was demonstrated to be CSPG4-dependent. Nuclear-localized
αCSPG4(scFv)-MAP tau interacted with tubulin and promoted polymerization, as shown by means
of co-immunoprecipitation and polymerization assays. Although less potent than CSPG4-ETA′,
αCSPG4(scFv)-MAP tau induced a partial G2/M arrest and eventually apoptosis in CSPG4+ cells.
Studies in tumor-xenografted mice demonstrated effective suppression of TNBC tumors, whereas
no effect was detected when treated with the MOCK control fusion protein αCSPG4(scFv)-SNAP.
In addition, the in vivo toxicity of αCSPG4(scFv)-MAP tau was comparable to that of its ETA′-based
counterpart for depletion of triple-negative breast cancer (TNBC) tumors (Figure 4). No detectable
side effects were observed regardless of treatment dose of αCSPG4(scFv)-MAP tau. In contrast, severe
detrimental effects were observed during αCSPG4-ETA′ treatment. Thus, αCSPG4(scFv)-MAP tau
showed to be both selectively efficacious against an otherwise therapy-resistant cancer type, with little
or no apparent systemic toxicity.
The benefits associated with humanization of ITs have led to further exploration into
CSPG4-targeting hCFP development. Other candidates recently being investigated as suitable hCFP
effector domains include Granzyme B (GrB), a serine protease secreted by cytotoxic lymphocytes [56]
and angiogenin (Ang), a human ribonuclease with a wide range of roles in biosynthesis and
stress-induced apoptosis [38–40]. The natural killer GrB, in fusion with a scFv, has been shown
to effectively deplete hematological tumors [41,57] and is undergoing evaluation for treatment of
solid tumors [56]. Ang, which induces apoptosis by degrading tRNA, has also been shown to exhibit
cytotoxicity upon delivery via a disease-specific scFv, while producing no immunogenicity or off-target
toxicity [38,43,58]. Both these cytotoxic effectors are subject to endogenous inhibition as a tumor
survival mechanism and the most recent stages of proofing have involved modifications to reduce
sensitivity to inhibition [44].
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respect, the immune system has been hailed for its stringent spatial and temporal regulation of
its highly potent effector echanisms. Cytotoxic T-cells, in particular, appear to be perfectly equipped
for efficient and directed cancer cell destruction. After TCR-mediated specific recognition and
appropriate co-stimulatory confirmation, efficient target cell elimination is achieved via membranolytic
pro-apoptotic effector molecules like perforins and granzymes and/or via receptor-mediated apoptosis
induction through so-called death receptors, like FAS, TNFR and TRAILR. Targeted anticancer
strategies using these death-inducing ligands, such as TRAIL, therefore possess considerable appeal.
3.3. Soluble TRAIL for Cancer Therapy
TRAIL is expressed as a type II transmembrane protein on immune effector cells, whereas
proteolytic processing or alternativ splicing ay yield soluble forms of TRAIL in vivo. Soluble forms
of TRAIL appear to retain potent antitumor ctivity with no minimal toxicity towards nor al
cells in numerous pre-clinical models. T t ke full adva tage of TRAIL-based approaches, various
charact istics of TRAILR/TRAIL system sho ld be taken into account, particularly the ubiquit s
expression of TRAIL receptors, the differential cross-li king requirements of agonistic receptors
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TRAIL-R1 (DR4) and TRAIL-R2 (DR5) and lastly, the solution behavior of certain sTRAIL preparations.
These factors considered, an increasing number of researchers (some of the authors included) have
constructed TRAIL fusion proteins, designated scFv:sTRAIL, comprising anticancer scFv antibody
fragment genetically fused to the N-terminus of human soluble TRAIL (Figure 5).
3.4. CSPG4-Restricted Apoptosis Induction by αMCSP:sTRAIL
ScFv:sTRAIL fusion proteins are equipped with the capacity to activate agonistic TRAIL
receptors after specific binding to a preselected cell surface-expressed tumor-associated antigen.
Disease-specific apoptosis induction by scFv:sTRAIL fusion proteins has been demonstrated for
various malignancies, including αMCSP:sTRAIL which targets melanoma featuring over-expression
of CSPG4 [45]. Binding of αMCSP:sTRAIL converts this soluble and conditionally-inactive fusion
protein into a membrane-bound form of TRAIL which is capable of signaling apoptosis not only
through TRAIL-R1 but also through TRAIL-R2. Indeed, incubation of a series of melanoma cell
lines with αMCSP:sTRAIL resulted in potent and MCSP-restricted apoptosis induction within 16 h.
Treatment with αMCSP:sTRAIL was accompanied by a rapid dephosphorylation of Focal adhesion
kinase (FAK), a kinase that has been implicated in the malignant phenotype of MCSP-expressing
melanoma cells. Importantly, already at picomolar concentrations αMCSP:sTRAIL reduced
anchorage-independent growth of melanoma cells by 50%. In contrast, in the same experiment
an over 100-fold higher concentration of soluble TRAIL was unable to inhibit colony formation.
In xenograft mouse models with established A375M xenografted melanoma tumors, daily
in vitro treatment with only 0.14 mg/kg/day αMCSP:sTRAIL resulted in a significant tumor growth
retardation that was synergized when this treatment was combined with rimcazole, a σ-1 receptor
antagonist that is currently evaluated in clinical trials for various cancers.
Importantly, size-exclusion chromatography demonstrated that αMCSP:sTRAIL was produced
as thermodynamically stable homogeneous trimers when excreted by eukaryotic production cells.
Homotrimeric fusion proteins showed the expected molecular weight of ~180 kDa, which may prevent
renal clearance likely resulting in an improved half-life of scFv:sTRAIL compared to conventional
soluble TRAIL preparations.
Stable trimeric scFv:sTRAIL fusion proteins like αMCSP:sTRAIL contain 3 identical tumor
targeting scFv domains. This trivalency may promotes accumulation of this fusion protein at the cell
surface of MCSP-overexpressing tumor cells due to the associated avidity effect. Increased avidity is
known to be beneficial for in vivo tumor targeting in many antibody-based therapeutic strategies [59].
Typically, on cancer cells the number target antigens like MCSP greatly exceed the number of
TRAIL receptor molecules. Consequently, upon MCSP-directed binding of αMCSP:sTRAIL a net
surplus of sTRAIL domains remains present to allow for subsequent activation of agonistic TRAIL
receptors on neighboring tumor cells. This so-called bystander effect has the potential to also eliminate
neighboring tumor cells that lack target antigen expression and which would otherwise escape from
targeted therapy (Figure 3). Exceptional potent bystander of scFv:sTRAIL has been demonstrated both
in vitro and in vivo for various malignancies [45,60–62]. Taken together, CSPG4-directed scFv:sTRAIL
fusion proteins appear to be a favorable format for the targeted and safe elimination of cancer cells
with heterogeneous expression of MCSP.
3.5. CSPG4-Restricted Apoptosis Induction by Bispecific Antibody MCSPxDR5
Pro-apoptotic activation of TRAIL-receptors for cancer therapy has been evaluated for both soluble
forms of recombinant TRAIL and agonistic αTRAIL-receptor antibodies directed against DR4 or DR5.
In particular, a series of agonistic αDR5 antibodies have been developed, including conatumumab,
drozitumab, tigatuzumab and lexatumumab. Early phase clinical trials indicate good tolerability of
these antibodies in patients, but also a lack of sufficient clinical efficacy. This appears to be related
to the fact that these agonistic αDR5 antibodies have no tumor-selective binding activity themselves,
whereas TRAIL receptors are ubiquitously expressed on normal tissue. As a result, relatively high
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concentrations of agonistic αDR5 antibodies maybe needed to overcome the target antigen sink formed
by DR5 expressed on normal cells. Moreover, similar to sTRAIL, in order to gain therapeutic activity
agonistic αDR5 antibodies such as tigatuzumab require secondary crosslinking e.g., by binding to
FcχR receptors as present on myeloid effector cells.
As a result, a novel bispecific antibody-based approach was developed that promotes
CSPG4-directed pro-apoptotic activation of DR5. This entailed engineering of a novel recombinant
bispecific antibody, designated bsAb MCSPxDR5, that has both high binding affinity for the CSPG4 and
potent agonistic activity towards DR5. The mode-of-action of bsAb MCSPxDR5 involved high-affinity
binding to tumor cell surface-expressed CSPG4 with concomitant localized enhanced cross-linking
of DR5. Herein, binding of bsAb MCSPxDR5 to tumor cells appeared to be dominated by binding
to CSPG4.
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Figure 5. (A) Soluble TRAIL (sTRAIL, light blue) has limited pro-apoptotic capacity towards cancer
cells as it fails to effectively cross-link TRAIL-R2 (DR5, yellow). ScFv:sTRAIL fusion proteins, consisting
of sTRAIL recombinantly fused (as indicated by the dotted lines) to a scFv (heavy & light chains in
green & beige) specific for a tumor-associated cell surface antigen such as CSPG4 (indigo), are designed
to initiate cross-linking of agonistic TRAIL receptors only upon specific binding to the above-mentioned
preselected antigen; (B) A conventional agonistic anti-DR5 antibody like tigatuzumab (green) may
induce apoptosis in DR5-expressing cancer cells, but lacks tumor-selective binding activity. This may
explain the limited efficacy observed for this antibody in clinical trials. In contrast, bsAb MCSPxDR5,
which is composed of constant (green) and two serial variable regions (blue and red) with high
specificity for both CSPG4 (indigo) and DR5 (yellow), resulting in agonistic activity towards DR5 as
well as potent CSPG4-directed pro-apoptotic anticancer activity (solid arrows indicate agents which
induce apoptosis).
The antitumor activity of tumor-bound bsAb MCSPxDR5 could be further enhanced by
cross-linking of its human immunoglobulin G1 (IgG1) domain either by an artificial cross-linker or by
Fc receptors as present on myeloid immune effector cells. Moreover, various melanoma-relevant
drugs (bortezomib, valproic acid and vemurafenib) synergized the antitumor activity of bsAb
MCSPxDR5. Importantly, MCSPxDR5 induced potent apoptosis in 11 out of 11 MCSP-expressing
primary patient-derived melanoma cells, that was further enhanced after secondary cross-linking of
its human IgG1 Fc domain. Of note, the fully functional human IgG1 Fc domain present in bsAb
MCSPxDR5 allows for ADCC- and CDC-mediated elimination of cancer cells. Moreover, this Fc
domain contained the binding motif for recycling by the neonatal Fc receptor (FcRn), which is of
crucial importance for achieving appropriate half-lives in the circulation.
Current in vitro data indicate that MCSPxDR5 has potent CSGP4-directed pro-apoptotic activity
towards MCSPpos/DR5pos melanoma cells with essentially no or minimal toxicity towards various
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normal cells. Therefore, bsAb MCSPxDR5 may be of value for the targeted treatment of melanoma
and other CSPG4-expressing malignancies. However, more in-depth studies are needed to establish
appropriate efficacy and safe toxicity profile when applied in eligible cancer patients.
4. Discussion
While chemotherapy remains one of the most crucial treatment routes for cancer patients,
it often comes up against obstacles such as resistance (upregulation of tumor survival pathways),
recurrence (due to endurance of tumor subpopulations) and harmful side effects (due to lack of
drug specificity). Tumors that do not express the more common characteristic biomarkers (e.g.,
endocrine receptors) are resistant to existing chemotherapies. The understanding that tumors must
upregulate the expression of certain signaling proteins in order to meet their metabolic needs, provides
us with a plethora of tumor-associated antigens which exhibit differential expression in otherwise
receptor-negative cancers. Here we have described CSPG4, a trans-membrane protein involved in
numerous pro-oncogenic signaling pathways, as a target for recombinant immunotherapeutics in
aggressive, therapy-resistant cancers. CSPG4 is strongly associated with several hallmarks of advanced
cancer, including proliferation, invasion and metastasis. It is known to be overexpressed in several
types of melanoma, basal-like breast and several other highly aggressive cancers. Overexpression
of CSPG4 has been associated with hypomethylation of CpG islands in the promoter region [10],
while others have postulated that chromosomal translocations at 11q23, in a gene possibly encoding a
transcription factor that regulates CSPG4 transcription, may result in CSPG4 overexpression (based on
studies of patients with acute myeloid/lymphoblastic leukemia) [19,20].
The association of CSPG4 with typically treatment-resistant cancers and its putative
overexpression in CSCs qualify it as an ideal target for immunotherapy. Treatment of melanoma,
TNBC and mesothelioma with mAb 9.2.27 [16], mAb 225.28 [18] and TP41.2 [21], respectively, has
been shown to suppress CSPG4-mediated cancer progression. However, the antigen-specificity of
immunotherapy, including treatment with disease-specific ITs (the primary focus of this review), begs
the consideration of potential detrimental side-effects of CSPG4-targeted therapy on non-malignant
CSPG4+ progenitor cells, glial stem cells and pericytes.
Naive pericytes, which provide structural support to normal vasculature, express relatively
low levels of CSPG4, whereas activated pericytes, mobilized during wound healing and tumor
angiogenesis [14], express higher levels of CSPG4 [4]. A slight growth decrease in CSPG4− melanoma
tumors (in a mouse model exposed to anti-CSPG4 immunotherapy) was observed by Wang et al. [4],
suggesting that the depletion of activated pericytes may suppress angiogenesis (a crucial feature
of tumors) while also reducing the number of viable pericytes lining blood vesicles which may
sensitize tumors to penetrating therapeutic agents. This and previous studies appear to imply that
collateral toxicity to pericytes may not be detrimentally harmful to the patient and may in fact enhance
tumor-eradication by ITs.
A similar outcome has been predicted for activated macrophages/microglia, which express NG2
(based on studies in mouse and rat brains). Systemic insult, such as tissue damage and neoplasm
regeneration (such as following radiation therapy), induces the recruitment of activated macrophages
to the site to neutralize the threat. However, factors present in the tumor microenvironment have been
known to reprogram macrophages to cease their attack on the tumor [63]. These tumor-associated
macrophages (taMΦ), including microglia recruited during CNS regeneration, proceed to secrete
factors that promote tumor survival and progression. NG2 expression is upregulated in taMΦ [55] with
respect to normal macrophages, which may target them for eradication at lower serum concentrations
of ITs than naïve macrophages.
No adverse side effects have as yet been reported in immunotherapeutic studies targeting CSPG4
in multiple cancers [18,54,64], with the exception of potential immunogenicity caused by pathogenic
cytotoxic effectors. However, in vivo studies are typically short-to-medium term mouse trials and do
not provide information on the long-term impact on development or immunity. The conclusion may
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lie in differential expression: since NG2/CSPG4 have multiple tumor-promoting influence, the benefits
of targeting cells which have upregulated CSPG4 may overshadow any non-tumor specific binding.
An anti-CSPG4(scFv) armed with a bacterial virulence factor has exhibited promising anticancer
activity in RMS (Brehm et al.) [24]. However, although virulence factors are very potent cytotoxic
effectors, their native binding and penetrative abilities tend to produce off-target effects and collateral
toxicity. Deletion of the cell-binding domain I (such as in the case of MCSP-ETA′) does alleviate this
issue by rendering the IT reliant on its targeting moiety (scFv) for binding and internalization, thereby
reducing off-target binding. To further complicate matters, as non-human proteins bacterial toxins are
inclined to induce production of neutralizing antibodies which sequester and inactivate the drug, thus
limiting the number of treatment cycles that can be effectively administered [65]. This immunogenic
effect can be somewhat reduced by identifying B-cell epitopes within the fusion protein and depleting
them by mutagenesis [49].
In the interest of enhancing prolonged drug efficacy, complete elimination of immunogenicity and
off-target toxicity can be achieved by replacing the bacterial toxin with an apoptosis-inducing human
protein [38]. Recently, hCFPs have been shown to exhibit anticancer activity inTNBC [54], RMS [50,56]
and leukemia [40,57], while notably no immunogenic effects were observed in these studies.
While reducing immunogenicity and off-target activity, exchanging a bacterial toxin for a less
immunogenic human effector protein introduces additional obstacles that limit the potency of hCFPs.
Bacterial toxins, once inside the cell, can translocate through subcellular membranes to access their
subcellular target compartment, where they produce high toxic potency—a feature lacking in human
proteins. Several strategies have been described by which it may be possible to enhance the antitumor
efficacy of hCFPs in order to match (or even exceed) that of bacterial ITs, while minimizing off-target
toxicity [66]. Some of the key obstacles and associated improvements are described below:
Internalization typically requires cross-linking of multiple ligand-bound receptors (or
antibody-bound antigens) to activate clathrin recruitment and induce receptor-mediated endocytosis [67].
Binding of multiple receptors can be achieved by modifying the length (and thereby rigidity) of the
linkers between VH and VL regions to induce formation of bi- and trivalent scFv’s (described in detail
in [68]). Monovalent ITs, such as those recently published using targeting CSPG4, are poorly internalized
into target cells in comparison to the multivalent scFv [69,70].
Subcellular routing determines the delivery of the hCFP to its effective target compartment.
Internalized proteins remaining in the endosome are doomed to lysosomal degradation, hence effective
drug deployment requires endosomal escape, re-routing & translocation of the hCFP within the cell.
These requirements could potentially be approached by including hydrophobic and cleavable elements
in the hCFP architecture (reviewed in [71]). The translocation domains of virulence factors (such as
ETA, ricin A and DT) can be mimicked in a recombinant human protein in order to (a) promote
retrograde transport from endosome to the ER by introduction of a C-terminal KDEL signal and
(b) facilitate membrane translocation from the ER into to the target compartment (s) by means of
selectively-exposed translocatable domains. The latter forms part of an adaptor which links the scFv
to the effector protein, and consists (in its simplest form) of an endosomal cleavable domain adjacent
to a membrane translocation peptide [72], resulting in removal of the scFv post-internalization and
cytosolic delivery of the smallest effective fraction of the hCFP.
Enzymatic activity may be influenced via various methods involving modification of the cytolytic
effector peptide in order to reduce its sensitivity to endogenous inhibitors and/or boost its affinity
for catalytic substrates [73,74]. Granzyme B (R201K) [44,57] and angiogenin (G85R/G86R and
Q117G) [39,40] are examples pro-apoptotic proteins which have undergone such modifications to
enhance their cytolytic activity. Further modifications of angiogenin are currently undergoing cell
model screening in fusion with αCSPG4 (scFv) for improved cytolytic efficacy against several cancers.
Somewhat impervious to most of the above-mentioned obstacles are CSPG4-directed TRAIL
fusions proteins, which need only contact the TRAIL death receptor in order to induce apoptosis The
αCSPG4:sTRAIL fusion protein is a fully-human tumor-directed anticancer agent which exacts potent
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pro-apoptotic activity when bound to the cell surface of a malignant cell. Importantly, off-target binding
may not result in undesirable cytotoxic effects, since normal cells appear to be largely resistant to
TRAIL-induced apoptosis. Therapeutic activity of scFv:sTRAIL is independent of both internalization
and intracellular routing, although internalization does not appear to inhibit its activity. Moreover,
the anticancer activity of scFv:sTRAIL fusion protein synergizes with the activity of a large variety of
clinically used anticancer agents, as well as with numerous agents under preclinical investigation.
Finally, therapeutic CSPG4-directed cancer cell death may also be achieved using a bsAb-based
approach as is exemplified by bsAb MCSPxDR5 that can exert strong and selective DR5-dependent
cytotoxic activity against CSPG4-expressing melanoma cells. Crosslinking of the antibody with
Fcγ-receptorsincreased the cytotoxic potential further, without compromising its selectivity.
This approach may offer an immunotherapeutic approach that combines several mutually reinforcing
anticancer activities, including delivering the death receptor agonist to the malignant cell population,
potent activation of DR5-mediated cell death signaling, and recruitment of Fcγ-receptor-carrying
immune cells that can mount an immune response against the tumor cells.
5. Conclusions
Cancer, as a group of diseases sharing molecular similarities but highly variable prognoses, poses
a massive socio-economic drain, necessitating improved therapeutic strategies with increased potency
and reduced side effects. CSPG4 represents a highly useful marker of aggressive and motile cancers,
thus offering an excellent opportunity to target cancers that are notoriously resistant to conventional
therapies. In this respect, hCFPs, TRAIL fusion proteins and DR5-agonistic bispecific antibodies
targeted at CSPG4 are highly promising candidates for the treatment of highly aggressive cancers with
a high recurrence rate and poor prognosis.
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